Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  BioDrugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 18031189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The design and development of an immunosuppressive drug, mycophenolate mofetil

  2004cited by this paper
• Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

  1999cited by this paper
• Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.

  1999cited by this paper
• Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.

  1999cited by this paper
• Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial.

  1999cited by this paper
• Comparison of two corticosteroid regimens in combination with CellCept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double-blind, randomized, multi-center study. M 55002 Study Group.

  1999cited by this paper
• Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.

  1999cited by this paper
• Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells.

  1999cited by this paper
• Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups.

  1999cited by this paper
• Improvement of drug-induced chronic renal failure in lung transplantation.

  1999cited by this paper
• Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients.

  1999cited by this paper
• A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

  1999cited by this paper
• Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation.

  1999cited by this paper
• Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.

  1999cited by this paper
• Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group.

  1999cited by this paper
• Induction of inosine monophosphate dehydrogenase activity after long‐term treatment with mycophenolate mofetil

  1999cited by this paper
• Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group.

  1999cited by this paper
• Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.

  1999cited by this paper
• Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy.

  1999cited by this paper
• Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report.

  1999cited by this paper
• Alterations of Endothelial Nucleotide Levels by Mycophenolic Acid Result in Changes of Membrane Glycosylation and E-Selectin Expression

  1999cited by this paper
• Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells.

  1999cited by this paper
• Cellcept enhances the rate of apoptosis in T cells after renal transplantation.

  1999cited by this paper
• Dendritic cells as regulators of immune reactivity: implications for transplantation.

  1999cited by this paper
• Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

  1999cited by this paper
• Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.

  1999cited by this paper
• One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation.

  1999cited by this paper
• Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.

  1999cited by this paper
• Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.

  1999cited by this paper
• Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite.

  1999cited by this paper
• Rethinking chronic allograft nephropathy: the concept of accelerated senescence.

  1999cited by this paper
• Nonnephrotoxic, nonatherogenic maintenance therapy in kidney-transplanted patients using MMF-monotherapy: a pilot study.

  1999cited by this paper
• Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.

  1999cited by this paper
• Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mofetil and cyclosporine.

  1998cited by this paper
• Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients.

  1998cited by this paper
• A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.

  1998cited by this paper
• Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.

  1998cited by this paper
• A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.

  1998cited by this paper
• Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses

  1998cited by this paper
• Pancreas transplantation: a review.

  1998cited by this paper
• Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients.

  1998cited by this paper
• Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients with Delayed Graft Function

  1998cited by this paper
• Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring.

  1998cited by this paper
• Chronic renal allograft rejection: no response to mycophenolate mofetil.

  1998cited by this paper
• Mycophenolate mofetil's effect on accelerated heart allograft rejection and rejection markers in the rat.

  1998cited by this paper
• A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

  1998cited by this paper
• Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation.

  1998cited by this paper
• Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.

  1998cited by this paper
• Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.

  1998cited by this paper
• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  1998cited by this paper
• A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1998cited by this paper
• Endothelial activation and cytokine expression in human acute cardiac allograft rejection

  1998cited by this paper
• Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat.

  1998cited by this paper
• Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation.

  1998cited by this paper
• Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis

  1998cited by this paper
• A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.

  1998cited by this paper
• Mycophenolate mofetil in pancreas transplantation.

  1998cited by this paper
• The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function

  1998cited by this paper
• Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.

  1998cited by this paper
• Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction.

  1998cited by this paper
• A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report.

  1998cited by this paper
• Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation.

  1998cited by this paper
• Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat.

  1998cited by this paper
• Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression.

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998cited by this paper
• Pediatric renal transplantation without steroids

  1998cited by this paper
• Simultaneous pancreas/kidney transplantation: comparison of mycophenolate mofetil versus azathioprine.

  1998cited by this paper
• Drug monitoring of mycophenolic acid in the early period after renal transplantation.

  1998cited by this paper
• Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy.

  1998cited by this paper
• Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.

  1998cited by this paper
• New immunosuppressive agents in pediatric renal transplantation.

  1998cited by this paper
• Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients.

  1998cited by this paper
• Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report.

  1998cited by this paper
• Trough blood concentrations in long-term treatment with mycophenolate mofetil.

  1998cited by this paper
• Cardiac graft vasculopathy: aetiologic factors and therapeutic approaches.

  1998cited by this paper
• Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.

  1998cited by this paper
• Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.

  1998cited by this paper
• Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.

  1998cited by this paper
• Tolerance of mycophenolate mofetil is dependent on kidney function.

  1998cited by this paper
• Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group.

  1998cited by this paper
• Cyclosporin nephrotoxicity: pathophysiology and comparison with FK‐506

  1998cited by this paper
• FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group.

  1998cited by this paper
• Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients.

  1998cited by this paper
• Pharmacokinetics of mycophenolate mofetil in heart transplant recipients.

  1998cited by this paper
• Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

  1997cited by this paper
• Mycophenolate mofetil monotherapy significantly decreases the immune response of acute rejection in rat liver allografts.

  1997cited by this paper
• Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.

  1997cited by this paper
• Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients.

  1997cited by this paper
• Prevention of transplant rejection: current treatment guidelines and future developments.

  1997cited by this paper
• Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation.

  1997cited by this paper
• Use of hypothermic circulatory arrest for cerebral protection during aortic surgery.

  1997cited by this paper
• A novel approach to the treatment of chronic allograft nephropathy.

  1997cited by this paper
• Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor.

  1997cited by this paper
• Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy.

  1997cited by this paper
• Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

  1997cited by this paper
• Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.

  1997cited by this paper
• FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.

  1997cited by this paper
• Tacrolimus rescue therapy for renal allograft rejection--five-year experience.

  1997cited by this paper
• Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity.

  1997cited by this paper
• Mycophenolate mofetil rescue therapy in liver transplant recipients.

  1997cited by this paper

• The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model

  2017cites this paper
• Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation

  2017cites this paper
• Management of high-risk corneal transplantation.

  2017cites this paper
• Presence of T-275A and C-2152T Polymorphisms of the Promoter Region of Uridine Diphosphate-Glucuronosyltransferase 1A9 Increases Mortality From Digestive Tumors: Results After 10 Years of Follow-up in a Renal Transplant Population.

  2016cites this paper
• Mycophenolic acid derivative 118 improves outcome of skin grafts by suppressing IL-17 production

  2013cites this paper
• Identification of the Molecular Mechanisms underlying the Gastrointestinal Toxicity of the Immunosuppressants Mycophenolate Mofetil and Enteric-coated Mycophenolate Sodium using a Proteo-Metabolomic Approach

  2013influential citation
• Modulation of Wound Healing Process in Glaucoma Filtration Surgery: Review

  2013cites this paper
• Nebulization of mycophenolate mofetil inhalation suspension in rats: comparison with oral and pulmonary administration of Cellcept®.

  2013cites this paper
• Mycophenolate Sodium Delayed Release

  2012influential citation
• Mycophenolate Mofetil

  2012influential citation
• Enteric-Coated Mycophenolate Sodium

  2012cites this paper
• Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ.

  2011cites this paper
• Role of mycophenolate mofetil in the treatment of autoimmune hepatitis.

  2011cites this paper
• Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

  2011cites this paper
• Drug monitoring in systemic lupus erythematosus: a systematic review.

  2011cites this paper
• Mycophenolate and Tacrolimus for Graft-Versus-Host Disease Prophylaxis for Elderly After Cord Blood Transplantation: A Matched Pair Comparison With Tacrolimus Alone

  2011cites this paper
• Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients.

  2009cites this paper
• Trasplante hepático experimental en el cerdo con donante a corazón parado. Efecto de diversas modificaciones de la bomba de derivación cardiopulmonar durante la recirculación sobre la viabilidad del injerto hepático.

  2009cites this paper
• Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study

  2009cites this paper
• Actualidad en el tratamiento de la nefritis lúpica proliferativa

  2009cites this paper
• Drug discovery from natural sources

  2006cites this paper
• Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

  2005cites this paper
• Mycophenolate sodium delayed release: prevention of renal transplant rejection.

  2005cites this paper
• Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.

  2005cites this paper
• MANAGEMENT OF REFRACTORY SYSTEMIC RHEUMATIC DISEASES

  2003cites this paper
• Disappearance of measurable mycophenolate mofetil (Cell Cept) in a patient with a renal transplant and an ileostomy.

  2002cites this paper
• Cytotoxic therapy of lupus nephritis: recent developments.

  2002cites this paper
• Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model

  2002cites this paper
• Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.

  2002cites this paper
• Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.

  2002cites this paper
• Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

  2002cites this paper
• In Vivo Higher Glucuronidation of Mycophenolic Acid in Male Than in Female Recipients of a Cadaveric Kidney Allograft and Under Immunosuppressive Therapy With Mycophenolate Mofetil

  2001cites this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cites this paper
• Comparative efficacy of mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) with and without cyclosporine in rat transplantation models.

  2001cites this paper
• A specific artificial antibody toward mycophenolic acid prepared by molecular imprinting

  2000cites this paper
• Antithymocyte Globulin (Rabbit)

  2000cites this paper
• Quantification of HIV-1 RNA using a homogeneous single-tube assay

  2000cites this paper
• Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

  2000cites this paper
• Chronic rejection of the liver: the role of immunosuppression.

  2000cites this paper
• Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

  1999cites this paper